vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and PTC THERAPEUTICS, INC. (PTCT). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $164.7M, roughly 1.0× PTC THERAPEUTICS, INC.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -22.7%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -11.5%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
ESPR vs PTCT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $164.7M |
| Net Profit | — | $-135.0M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | -43.3% |
| Net Margin | — | -82.0% |
| Revenue YoY | 143.7% | -22.7% |
| Net Profit YoY | — | -104.8% |
| EPS (diluted) | $0.32 | $-1.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $164.7M | ||
| Q3 25 | $87.3M | $211.0M | ||
| Q2 25 | $82.4M | $178.9M | ||
| Q1 25 | $65.0M | $1.2B | ||
| Q4 24 | $69.1M | $213.2M | ||
| Q3 24 | $51.6M | $196.8M | ||
| Q2 24 | $73.8M | $186.7M | ||
| Q1 24 | $137.7M | $210.1M |
| Q4 25 | — | $-135.0M | ||
| Q3 25 | $-31.3M | $15.9M | ||
| Q2 25 | $-12.7M | $-64.8M | ||
| Q1 25 | $-40.5M | $866.6M | ||
| Q4 24 | — | $-65.9M | ||
| Q3 24 | $-29.5M | $-106.7M | ||
| Q2 24 | $-61.9M | $-99.2M | ||
| Q1 24 | $61.0M | $-91.6M |
| Q4 25 | 50.6% | -43.3% | ||
| Q3 25 | -11.4% | 1.4% | ||
| Q2 25 | 8.6% | -19.5% | ||
| Q1 25 | -34.0% | 82.5% | ||
| Q4 24 | -6.4% | -76.2% | ||
| Q3 24 | -31.0% | -27.7% | ||
| Q2 24 | 3.5% | -21.5% | ||
| Q1 24 | 52.5% | -21.6% |
| Q4 25 | — | -82.0% | ||
| Q3 25 | -35.9% | 7.5% | ||
| Q2 25 | -15.4% | -36.3% | ||
| Q1 25 | -62.2% | 73.7% | ||
| Q4 24 | — | -30.9% | ||
| Q3 24 | -57.2% | -54.2% | ||
| Q2 24 | -83.9% | -53.1% | ||
| Q1 24 | 44.3% | -43.6% |
| Q4 25 | $0.32 | $-1.63 | ||
| Q3 25 | $-0.16 | $0.20 | ||
| Q2 25 | $-0.06 | $-0.83 | ||
| Q1 25 | $-0.21 | $10.04 | ||
| Q4 24 | $-0.14 | $-0.85 | ||
| Q3 24 | $-0.15 | $-1.39 | ||
| Q2 24 | $-0.33 | $-1.29 | ||
| Q1 24 | $0.34 | $-1.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $1.9B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $-205.3M |
| Total Assets | $465.9M | $2.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $1.9B | ||
| Q3 25 | $92.4M | $1.7B | ||
| Q2 25 | $86.1M | $2.0B | ||
| Q1 25 | $114.6M | $2.0B | ||
| Q4 24 | $144.8M | $1.1B | ||
| Q3 24 | $144.7M | $1.0B | ||
| Q2 24 | $189.3M | $1.1B | ||
| Q1 24 | $226.6M | $884.8M |
| Q4 25 | $-302.0M | $-205.3M | ||
| Q3 25 | $-451.4M | $-155.8M | ||
| Q2 25 | $-433.5M | $-206.5M | ||
| Q1 25 | $-426.2M | $-185.8M | ||
| Q4 24 | $-388.7M | $-1.1B | ||
| Q3 24 | $-370.2M | $-1.1B | ||
| Q2 24 | $-344.2M | $-980.2M | ||
| Q1 24 | $-294.3M | $-893.9M |
| Q4 25 | $465.9M | $2.9B | ||
| Q3 25 | $364.0M | $2.6B | ||
| Q2 25 | $347.1M | $2.6B | ||
| Q1 25 | $324.0M | $2.7B | ||
| Q4 24 | $343.8M | $1.7B | ||
| Q3 24 | $314.1M | $1.8B | ||
| Q2 24 | $352.3M | $1.9B | ||
| Q1 24 | $373.1M | $1.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $-34.3M |
| Free Cash FlowOCF − Capex | — | $-36.6M |
| FCF MarginFCF / Revenue | — | -22.3% |
| Capex IntensityCapex / Revenue | 0.0% | 1.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $702.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $-34.3M | ||
| Q3 25 | $-4.3M | $-66.3M | ||
| Q2 25 | $-31.4M | $-58.3M | ||
| Q1 25 | $-22.6M | $870.1M | ||
| Q4 24 | $-35.0M | $-30.0M | ||
| Q3 24 | $-35.3M | $-77.0M | ||
| Q2 24 | $-7.2M | $-71.5M | ||
| Q1 24 | $53.8M | $70.8M |
| Q4 25 | — | $-36.6M | ||
| Q3 25 | — | $-69.7M | ||
| Q2 25 | — | $-59.6M | ||
| Q1 25 | — | $868.4M | ||
| Q4 24 | — | $-33.8M | ||
| Q3 24 | $-35.5M | $-77.5M | ||
| Q2 24 | $-7.3M | $-78.8M | ||
| Q1 24 | $53.8M | $61.2M |
| Q4 25 | — | -22.3% | ||
| Q3 25 | — | -33.1% | ||
| Q2 25 | — | -33.3% | ||
| Q1 25 | — | 73.8% | ||
| Q4 24 | — | -15.8% | ||
| Q3 24 | -68.7% | -39.4% | ||
| Q2 24 | -9.9% | -42.2% | ||
| Q1 24 | 39.0% | 29.1% |
| Q4 25 | 0.0% | 1.4% | ||
| Q3 25 | 0.0% | 1.6% | ||
| Q2 25 | 0.0% | 0.7% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.0% | 1.8% | ||
| Q3 24 | 0.3% | 0.3% | ||
| Q2 24 | 0.1% | 4.0% | ||
| Q1 24 | 0.1% | 4.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | -4.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
PTCT
Segment breakdown not available.
